Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Prevalence of human leukocyte antigen HLA-B*57:01 in individuals with HIV in West and Central Africa

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • Contributors:
      Université de Lomé Togo; Université Nazi Boni (Bobo-Dioulasso) (UNB); Université Félix Houphouët-Boigny (UFHB); Université d’Abomey-Calavi = University of Abomey Calavi (UAC); Site de recherche ANRS Abidjan, Côte d'Ivoire; Centre Hospitalier Universitaire Souro Sanou Bobo-Dioulasso (CHUSS); Université des Sciences de la Santé Libreville, Gabon; Team MORPH3EUS (INSERM U1219 - UB - ISPED); Bordeaux population health (BPH); Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)
    • بيانات النشر:
      HAL CCSD
      BioMed Central
    • الموضوع:
      2021
    • Collection:
      Inserm: HAL (Institut national de la santé et de la recherche médicale)
    • نبذة مختصرة :
      International audience ; Background: The presence of the human leukocyte antigen HLA-B*57:01 is associated with the development of a hypersensitivity reaction to abacavir (ABC). Limited data exist on HLA-B*57:01 prevalence in individuals with HIV-1 in Africa. This study aimed to estimate HLA-B*57:01 prevalence in individuals with HIV-1 in West and Central Africa. Methods: A cross-sectional study was conducted in four countries in West and central Africa (Burkina-Faso, Côte d'Ivoire, Gabon, and Togo) from January 2016 to February 2020 to determine the status of HLA-B*57:01 in adults with HIV-1. The presence of HLA-B*57:01 was determined by using Single Specific Primer-Polymerase Chain Reaction (SSP-PCR) in blood samples. Prevalence rates were stratified based on country. Results: A total of 4016 (69.8% women) individuals with HIV were enrolled. Their median age was 45, and the interquartile range was 38-52. We included 500 (12.4%) patients in Burkina-Faso, 1453 (36.2%) in Côte d'Ivoire, 951 (23.7%) in Gabon, and 1112 (27.7%) in Togo. The overall HLA-B*57:01 prevalence was 0.1% [95% CI: 0.0-0.2%]. The prevalence of HLA-B*57:01 was similar according to the four countries. Only one case was reported in each country except Togo, with no cases. Conclusions: HLA-B*57:01 prevalence is low in individuals with HIV in West and central Africa, and there is no difference among countries. This study does not confirm the utility of HLA-B*57:01 allele testing for abacavir use in this region.
    • Relation:
      info:eu-repo/semantics/altIdentifier/pmid/34294032; inserm-03310669; https://inserm.hal.science/inserm-03310669; https://inserm.hal.science/inserm-03310669/document; https://inserm.hal.science/inserm-03310669/file/s12865-021-00427-7.pdf; PUBMED: 34294032; PUBMEDCENTRAL: PMC8299582
    • الرقم المعرف:
      10.1186/s12865-021-00427-7
    • Rights:
      info:eu-repo/semantics/OpenAccess
    • الرقم المعرف:
      edsbas.306E68C9